Ignite Creation Date:
2025-12-25 @ 2:20 AM
Ignite Modification Date:
2026-01-07 @ 7:00 AM
Study NCT ID:
NCT05118334
Status:
COMPLETED
Last Update Posted:
2023-02-23
First Post:
2021-11-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CIBI310H201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None